HALO — Halozyme Therapeutics Inc · P/E 15, rev $857.7M

Halozyme Therapeutics Inc (HALO) is a biotechnology company listed on US.

Latest reported HALO revenue for 2026-06-30 was $857.7M. Net income was $380.0M. HALO currently screens at market cap $7.10B and trailing P/E 15.3.

Use this HALO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the HALO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the HALO SEC filings page. Lician reads the product cache first so this HTML stays unique to Halozyme Therapeutics Inc even when a live quote feed is slow.

Halozyme Therapeutics Inc latest statements (FY2025)

Latest cached year on this hub. Full HALO income, balance, and cash tables.

  • Revenue$1.40B
  • Net Income$316.9M
  • Total Assets$2.53B
  • Total Debt$0
  • Free Cash Flow$644.6M

HALO recent filings